Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide

Molecular Immunology

Volumn 45, Issue 10, 2008, Pages 2861-2868

  Du, Jiamu ^a,b   Wang, Hao ^c   Zhong, Chen ^a   Peng, Baozhen ^a   Zhang, Meilan ^a   Li, Bohua ^c   Hou, Sheng ^c   Guo, Yajun ^c   Ding, Jianping ^a  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antibody structure; C2H7; CD20; Epitope

Indexed keywords

CD20 ANTIGEN; EPITOPE; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C2H7; RITUXIMAB; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; BURKITT LYMPHOMA; CHROMATOGRAPHY; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HYDROGEN BOND; HYDROPHILICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DETERMINATION; PROTEIN DOMAIN;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; CRYSTALLOGRAPHY, X-RAY; CYTOTOXICITY, IMMUNOLOGIC; EPITOPES; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MOLECULAR SEQUENCE DATA; PEPTIDES; RECOMBINANT FUSION PROTEINS;

EID: 41849098499     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2008.01.034     Document Type: Article

References (30)

1. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol. 273 (1997) 927-948
2. Anderson K.C., Bates M.P., Slaughenhoupt B.L., Pinkus G.S., Schlossman S.F., and Nadler L.M. Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation. Blood 63 (1984) 1424-1433
3. Binder M., Otto F., Mertelsmann R., Veelken H., and Trepel M. The epitope recognized by rituximab. Blood 108 (2006) 1975-1978
4. Brunger A.T., Adams P.D., Clore G.M., DeLano W.L., Gros P., Grosse-Kunstleve R.W., Jiang J.S., Kuszewski J., Nilges M., Pannu N.S., Read R.J., Rice L.M., Simonson T., and Warren G.L. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D54 (1998) 905-921
5. Clark E.A., Shu G., and Ledbetter J.A. Role of the Bp35 cell surface polypeptide in human B-cell activation. Proc. Natl. Acad. Sci. U.S.A. 82 (1985) 1766-1770
6. Collaborative Computational Project Number 4, 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D50 760-763.
7. Cragg M.S., Morgan S.M., Chan H.T., Morgan B.P., Filatov A.V., Johnson P.W., French R.R., and Glennie M.J. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101 (2003) 1045-1052
8. Cragg M.S., Walshe C.A., Ivanov A.O., and Glennie M.J. The biology of CD20 and its potential as a target for mAb therapy. Curr. Dir. Autoimmun. 8 (2005) 140-174
9. Du J., Wang H., Zhong C., Peng B., Zhang M., Li B., Huo S., Guo Y., and Ding J. Structural basis for recognition of CD20 by therapeutic antibody Rituximab. J. Biol. Chem. 282 (2007) 15073-15080
10. Jazirehi A.R., and Bonavida B. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Oncogene 24 (2005) 2121-2143
11. Jones T.A., Zou J.Y., Cowan S.W., and Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A47 (1991) 110-119
12. Kortemme T., and Baker D. A simple physical model for binding energy hot spots in protein-protein complexes. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 14116-14121
13. Laskowski R.A., Macarthur M.W., Moss D.S., and Thornton J.M. Procheck-a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26 (1993) 283-291
14. Li B., Wang H., Dai J., Ji J., Qian W., Zhang D., Hou S., and Guo Y. Construction and characterization of a humanized anti-human CD3 monoclonal antibody 12F6 with effective immunoregulation functions. Immunology 116 (2005) 487-498
15. Liu A.Y., Robinson R.R., Murray Jr. E.D., Ledbetter J.A., Hellstrom I., and Hellstrom K.E. Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity. J. Immunol. 139 (1987) 3521-3526
16. Maloney D.G. Follicular NHL: from antibodies and vaccines to graft-versus-lymphoma effects. Hematology 2007 (2007) 226-232
17. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D53 (1997) 240-255
18. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
19. Painter J., and Merritt E.A. Optimal description of a protein structure in terms of multiple groups undergoing TLS motion. Acta Crystallogr. D62 (2006) 439-450
20. Painter J., and Merritt E.A. TLSMD web server for the generation of multi-group TLS models. J. Appl. Crystallogr. 39 (2006) 109-111
21. Perosa F., Favoino E., Caragnano M.A., and Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood 107 (2006) 1070-1077
22. Polyak M.J., and Deans J.P. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. Blood 99 (2002) 3256-3262
23. Press O.W., Howell-Clark J., Anderson S., and Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83 (1994) 1390-1397
24. Reff M.E., Carner K., Chambers K.S., Chinn P.C., Leonard J.E., Raab R., Newman R.A., Hanna N., and Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83 (1994) 435-445
25. Sammond D.W., Eletr Z.M., Purbeck C., Kimple R.J., Siderovski D.P., and Kuhlman B. Structure-based protocol for identifying mutations that enhance protein-protein binding affinities. J. Mol. Biol. 371 (2007) 1392-1404
26. Stanfield R.L., Zemla A., Wilson I.A., and Rupp B. Antibody elbow angles are influenced by their light chain class. J. Mol. Biol. 357 (2006) 1566-1574
27. Teeling J.L., French R.R., Cragg M.S., van den Brakel J., Pluyter M., Huang H., Chan C., Parren P.W., Hack C.E., Dechant M., Valerius T., van de Winkel J.G., and Glennie M.J. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 104 (2004) 1793-1800
28. Teeling J.L., Mackus W.J., Wiegman L.J., van den Brakel J.H., Beers S.A., French R.R., van Meerten T., Ebeling S., Vink T., Slootstra J.W., Parren P.W., Glennie M.J., and van de Winkel J.G. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J. Immunol. 177 (2006) 362-371
29. Vagin A., and Teplyakov A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30 (1997) 1022-1025
30. Zafir-Lavie I., Michaeli Y., and Reiter Y. Novel antibodies as anticancer agents. Oncogene 26 (2007) 3714-3733